# CheckMate 9ER (NCT03141177)

> A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03141177
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Renal Cell Carcinoma
- Interventions: Nivolumab; Cabozantinib; Sunitinib; Ipilimumab
- Enrollment: 701
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- X threads: 95
- YouTube: 46
- Podcasts: 38

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-9er-nct03141177

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03141177", "email": "<work email>"}; the inbox owner confirms by the emailed link.